179
Views
7
CrossRef citations to date
0
Altmetric
Drug Evaluations

Gemtuzumab ozogamicin in non-acute promyelocytic acute myeloid leukemia

, MD & , MD
Pages 1369-1380 | Published online: 03 Aug 2011

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Yan Zhou & Jindřich Kopeček. (2013) Biological rationale for the design of polymeric anti-cancer nanomedicines. Journal of Drug Targeting 21:1, pages 1-26.
Read now
John R Adair, Philip W Howard, John A Hartley, David G Williams & Kerry A Chester. (2012) Antibody–drug conjugates – a perfect synergy. Expert Opinion on Biological Therapy 12:9, pages 1191-1206.
Read now

Articles from other publishers (5)

Michele Gottardi, Giorgia Simonetti, Alessandra Sperotto, Davide Nappi, Andrea Ghelli Luserna di Rorà, Antonella Padella, Marianna Norata, Maria Benedetta Giannini, Gerardo Musuraca, Francesco Lanza, Claudio Cerchione & Giovanni Martinelli. (2021) Therapeutic Targeting of Acute Myeloid Leukemia by Gemtuzumab Ozogamicin. Cancers 13:18, pages 4566.
Crossref
Victor Yip, M. Violet Lee, Ola M. Saad, Shuguang Ma, S. Cyrus Khojasteh & Ben-Quan Shen. (2021) Preclinical Characterization of the Distribution, Catabolism, and Elimination of a Polatuzumab Vedotin-Piiq (POLIVY®) Antibody–Drug Conjugate in Sprague Dawley Rats. Journal of Clinical Medicine 10:6, pages 1323.
Crossref
C D Godwin, R P Gale & R B Walter. (2017) Gemtuzumab ozogamicin in acute myeloid leukemia. Leukemia 31:9, pages 1855-1868.
Crossref
Ofir Wolach & Richard M. Stone. 2015. Targeted Therapy in Translational Cancer Research. Targeted Therapy in Translational Cancer Research 89 100 .
LeeRon Shefet-Carasso & Itai Benhar. (2015) Antibody-targeted drugs and drug resistance—Challenges and solutions. Drug Resistance Updates 18, pages 36-46.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.